Natural history and clinical features of aspirin-exacerbated respiratory disease

被引:0
|
作者
John M. Fahrenholz
机构
关键词
Aspirin-sensitive asthma; aspirin triad; nonsteroidal antiinflammatory drugs; adverse reactions;
D O I
暂无
中图分类号
学科分类号
摘要
Aspirin-exacerbated respiratory disease (AERD) is a clinical syndrome characterized by chronic rhinosinusitis, nasal polyposis, asthma and precipitation of asthma, and rhinitis attacks after ingestion of aspirin (ASA) and most other nonsteroidal antiinflammatory drugs (NSAIDs). Although precipitation of asthma attacks by ingestion of ASA and other NSAIDs is considered a hallmark of the syndrome, the respiratory mucosal inflammatory disease process begins and continues in the absence of ongoing or even intermittent exposure to ASA or NSAIDs. The typical patient with AERD is an adult who develops refractory chronic rhinitis in the third or fourth decade of life. The chronic rhinitis evolves into chronic eosinophilic rhinosinusitis with associated nasal polyposis. Anosmia appears in most patients. CT of the sinuses most often demonstrates pansinusitis and patients often undergo multiple sinus operations resulting in only limited temporary benefit. During the evolution of the sinus disease persistent asthma develops. Finally, if patients are exposed to ASA or NSAIDs acute respiratory reactions begin to occur. Despite subsequent avoidance of ASA and other NSAIDs, the respiratory mucosal inflammatory disease persists, often requiring systemic corticosteroids for control of both upper- and lower-respiratory tract symptoms. Adequate control of asthma can often only be accomplished with the simultaneous control of the associated rhinosinusitis. With few exceptions, once AERD develops it remains for the remainder of the patient’s life.
引用
收藏
页码:113 / 124
页数:11
相关论文
共 50 条
  • [41] Cellular interactions in aspirin-exacerbated respiratory disease
    Badrani, Jana H.
    Doherty, Taylor A.
    CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY, 2021, 21 (01) : 65 - 70
  • [42] Nasal Polyposis and Aspirin-Exacerbated Respiratory Disease
    Luskin, Kathleen
    Thakrar, Hiral
    White, Andrew
    IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA, 2020, 40 (02) : 329 - +
  • [43] Approach to desensitization in aspirin-exacerbated respiratory disease
    Scott, David R.
    White, Andrew A.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2014, 112 (01) : 13 - 17
  • [44] Mast Cells in Aspirin-Exacerbated Respiratory Disease
    Abud, Edsel M.
    White, Andrew A.
    CURRENT ALLERGY AND ASTHMA REPORTS, 2024, 24 (02) : 73 - 80
  • [45] Diagnostic Evaluation in Aspirin-Exacerbated Respiratory Disease
    Williams, Adam N.
    IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA, 2016, 36 (04) : 657 - +
  • [46] Aspirin-Exacerbated Respiratory Disease: Evaluation and Management
    Lee, Rachel U.
    Stevenson, Donald D.
    ALLERGY ASTHMA & IMMUNOLOGY RESEARCH, 2011, 3 (01) : 3 - 10
  • [47] An update on the epidemiology of aspirin-exacerbated respiratory disease
    White, Andrew A.
    AMERICAN JOURNAL OF RHINOLOGY & ALLERGY, 2017, 31 (05) : 299 - 301
  • [48] AN "EXCEPTIONAL" ASPIRIN-EXACERBATED RESPIRATORY DISEASE PATIENT
    Thakrar, H.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2019, 123 (05) : S134 - S134
  • [49] Perimenstrual Asthma in Aspirin-Exacerbated Respiratory Disease
    Eid, Ryan C.
    Palumbo, Marina L.
    Cahill, Katherine N.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2020, 8 (02): : 573 - +
  • [50] Omalizumab in the treatment of aspirin-exacerbated respiratory disease
    Bergmann, Karl-Christian
    Zuberbier, Torsten
    Church, Martin K.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2015, 3 (03): : 459 - 460